** MiRXES Holding 2629.HK climbs to HK$31.95 on HK debut, up 37.1% from offer price of HK$23.30
** Stock last up 31.8%, outpacing Hang Seng Index's .HSI 0.5% gain and Hang Seng Biotech index's .HSHKBIO 2.3% jump
** Singapore-headquartered micro ribonucleic acid (miRNA) tech co, which specialises in early cancer detection and precision medicine, sells 46.6 mln shares in global offering, raising HK$1.09 bln ($139.2 mln) for R&D, manufacturing, commercialisation of core product
** Jiangsu Hengrui Pharmaceuticals 1276.HK jumps to HK$60.5 on HK debut, up 37.3% from offer price of HK$44.05
** Chinese oncology drug developer sells 224.52 mln H-shares, raising HK$9.89 bln ($1.26 bln) for R&D, constructing production facilities
** Hengrui's Shanghai stock 600276.SS slips 1.6%
($1 = KH$7.8302)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。